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Abstract
Novel treatment options are needed for the successful therapy of patients with high-risk neuroblastoma. Here, we investigated the cyclin-
dependent kinase (CDK) inhibitor SNS-032 in a panel of 109 neuroblastoma cell lines consisting of 19 parental cell lines and 90 sublines with
acquired resistance to 14 different anticancer drugs. Seventy-three percent of the investigated neuroblastoma cell lines and all four investigated
primary tumor samples displayed concentrations that reduce cell viability by 50% in the range of the therapeutic plasma levels reported for
SNS-032 (<754 nM). Sixty-two percent of the cell lines and two of the primary samples displayed concentrations that reduce cell viability by 90%
in this concentration range. SNS-032 also impaired the growth of the multidrug-resistant cisplatin-adapted UKF-NB-3 subline UKF-NB-3rCDDP1000 in
mice. ABCB1 expression (but not ABCG2 expression) conferred resistance to SNS-032. The antineuroblastoma effects of SNS-032 did not depend
on functional p53. The antineuroblastoma mechanism of SNS-032 included CDK7 and CDK9 inhibition–mediated suppression of RNA synthesis
and subsequent depletion of antiapoptotic proteins with a fast turnover rate including X-linked inhibitor of apoptosis (XIAP), myeloid cell leukemia
sequence 1 (Mcl-1), baculoviral IAP repeat containing 2 (BIRC2; cIAP-1), and survivin. In conclusion, CDK7 and CDK9 represent promising drug
targets and SNS-032 represents a potential treatment option for neuroblastoma including therapy-refractory cases.
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Introduction
SNS-032 (BMS-387032) is an inhibitor of cyclin-dependent kinase 2
(CDK2), CDK7, and CDK9 that was shown to exert anticancer
effects in leukemia, lymphoma, multiple myeloma, glioblastoma, lung
cancer, osteosarcoma, and ovarian carcinoma cells [1–10], to exert
chemopreventive effects in a mouse model of colorectal cancer [11],
and to inhibit glioblastoma cell–induced angiogenesis [4]. The drug
is under investigation in clinical trials for the treatment of different
hematological and solid tumors [6,12–14]. Its mechanism of action
was suggested to depend primarily on interference with CDK7 and
CDK9 [5,12].
CDKs were suggested as therapeutic targets for the treatment of
neuroblastoma [15,16], the most frequent solid extracranial pediatric
cancer entity. About half of the patients are diagnosed with high-
risk disease associated with overall survival rates below 50% despite
myeloablative therapy and differentiation therapy using retinoids [17].
While many neuroblastomas respond initially well to therapy, acquired
drug resistance represents a major problem [18,19].
Here, we investigated the effects of SNS-032 in a panel of 109 neuro-
blastoma cell lines consisting of 19 parental neuroblastoma cell lines
and 90 sublines with acquired resistance to 14 different anticancer
drugs. SNS-032 affected neuroblastoma cell viability in cell lines and
primary tumor samples in therapeutic concentrations and in a xeno-
graft mouse model. High ABCB1 expression impaired the efficacy of
SNS-032, whereas it was modestly affected by ABCG2 expression
and not influenced by the cellular p53 status. SNS-032 exerted its
antineuroblastoma effects primarily through cytotoxic effects under
involvement of CDK7 and particularly CDK9 as therapeutic targets.
Materials and Methods
Drugs
The compounds were purchased from the following sources:
flubendazole from Enzo Life Sciences (Lörrach, Germany), SNS-032
and nutlin-3 from Selleck Chemicals through BIOZOL GmbH
(Eching, Germany), vincristine and cisplatin from TEVA GmbH
(Radebeul, Germany), doxorubicin from cell pharm (Bad Vilbel,
Germany), melphalan and topotecan from GlaxoSmithKline GmbH
and Co. KG (Munich, Germany), actinomycin D from Lundbeck
Pharmaceuticals Ireland Limited (Dublin, Ireland), verapamil from
Sigma-Aldrich (Munich, Germany), and Fumitremorgin C from
Merck Millipore (Darmstadt, Germany).
Cells
The MYCN-amplified neuroblastoma cell lines UKF-NB-2, UKF-
NB-3, UKF-NB-4, and UKF-NB-6 were established from patients with
stage 4 neuroblastoma [20–23]. UKF-NB-3 clone 1 and UKF-NB-3
clone 3 are p53 wild-type single cell-derived sublines of UKF-NB-3
[24]. Be(2)C, IMR-32, SH-SY5Y, SK-N-AS, and SK-N-SH cells were
obtained from American Type Culture Collection (ATCC; Manassas,
VA); CHP-134, Kelly, LAN2, NGP, and NMB cells from DMSZ
(Braunschweig, Germany); and GI-ME-N and LAN5 cells from ICLC
(Genova, Italy). IMR-5, NLF, and SHEP cells were kindly provided by
Dr Angelika Eggert (Universität Duisburg-Essen, Essen, Germany).
Neuroblastoma cell lines were adapted to growth in the presence
of anticancer drugs by continuous exposure to increasing drug con-
centrations as described previously [21,22,24]. All neuroblastoma cell
lines with acquired drug resistance were derived from the resistant
cancer cell line (RCCL) collection. The corresponding concentrations
that reduce cell viability by 50% (IC50) for the parental cells and their
drug-resistant sublines are provided in Table W1A.
All cells were propagated in Iscove’s modified Dulbecco’s medium
(IMDM) supplemented with 10% fetal calf serum (FCS), 100 IU/ml
penicillin, and 100 mg/ml streptomycin at 37°C. Cells were routinely
tested for mycoplasma contamination and authenticated by short
tandem repeat profiling.
p53-depleted neuroblastoma cells or neuroblastoma cells showing
high expression of ABCB1 [also known as multidrug resistance pro-
tein 1 (MDR1) or P-glycoprotein] or ABCG2 [also known as breast
cancer resistance protein (BCRP)] were established as described pre-
viously [25] using the Lentiviral Gene Ontology vector technology
(www.lentigo-vectors.de).
Fresh neuroblastoma cells (MYCN amplified) were isolated from
the bone marrow aspirate of four patients with metastasized Inter-
national Neuroblastoma Staging System (INSS) stage 4 neuroblastoma
following informed consent. Primary cells were cultivated in IMDM
supplemented with 10% FCS, 100 IU/ml penicillin, and 100 mg/ml
streptomycin at 37°C.
Mutation Analysis of p53
TP53 gene sequencing on cDNAs was performed as described
previously [26] using the following four pairs of primers: TP53
Ex2-3-f GTGACACGCTTCCCTGGAT and TP53 Ex2-3-r
TCATCTGGACCTGGGTCTTC; TP53 Ex4-5-f CCCTTCCC-
AGAAAACCTACC and TP53 Ex4-5-r CTCCGTCATGTGCTGT-
GACT; TP53 EX6-7f GTGCAGCTGTGGGTTGATT and TP53
Ex6-7r GGTGGTACAGTCAGAGCCAAC; Tp53 Ex8-9-f
CCTCACCATCATCACACTGG and TP53 Ex8-9-rGTCTGG-
TCCTGAAGGGTGAA. In addition, all cell lines were examined
for TP53 mutations by sequence analysis of genomic DNA. Each
amplicon was sequenced bidirectionally.
Viability Assay
Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) dye reduction assay after
120-hour incubation and modified as described previously [24].
ABCB1 Expression and Rhodamine 123 Accumulation
ABCB1 expression and rhodamine accumulation were detected as
described previously [25,27]. ABCB1 was detected by flow cytometry
using a primary mouse anti-ABCB1 antibody (Alexis Biochemicals
through AXXORA Deutschland, Lörrach, Germany) and a secondary
phycoerythrin (PE)–labeled goat anti-mouse antibody (R&D Systems,
Wiesbaden, Germany). Accumulation of the fluorescent ABCB1 sub-
strate rhodamine 123 was determined using ABCB1-expressing UKF-
NB-3rVCR10 cells. The cells were preincubated with SNS-032
or verapamil (ABCB1 inhibitor, positive control) for 30 minutes at
37°C before incubation with the fluorescent ABCB1 substrate rhoda-
mine 123 (1 μM) for another 30 minutes. Then, the cells were washed
twice with phosphate-buffered saline (PBS), fresh medium contain-
ing verapamil or SNS-032 was added, and the cellular fluorescence
was analyzed after a further 30 minutes by flow cytometry.
ABCB1-Ligand Docking
ABCB1-ligand docking study was carried out using three-dimensional
(3D) structures of mouse and human ABCB1 using MOE software
(ver 2011.10; Chemical Computing Group Inc, Montreal, Quebec).
The X-ray structures of the mouse homologue orthologue Abcb1a
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[28] were obtained from the protein data bank (PDB codes: 3G60,
3G61, and 3G5U; http://www.rcsb.org). The proteins 3G60 and
3G61 are in complex with cyclic peptide inhibitors cyclic-tris-(R)-vali-
neselenazole (QZ59-RRR) and cyclic-tris-(S)-valineselenazole (QZ59-
SSS), whereas 3G5U is in the absence of a ligand. The homology model
of the human ABCB1 structure was obtained from Bikadi et al. [29].
The protein and ligands were prepared for docking in MOE software.
Protein structures were loaded into the software where the crystal param-
eters were retained, hydrogen atoms were added, and the proteins were
titrated using default parameters of the software. To prepare the ligand,
atomic charge and energy minimization was performed using self-
consistent field (SCF) optimization (AM1 Hamiltonian). Maximum
distance for nonbonded interacting atoms was 4.5 Å. In the MOE
dock panel, the placement method was Triangle Matcher, the scoring
methodology was set to London dG as the first and the second scoring
functions, and the refinement methodology was set to MMFF94 force
field. The mean energies and the backbone root mean square deviation
of 30 best scoring poses were retained. The binding site was defined
in MOE software using the co-crystallized hexapeptide inhibitors,
QZ59-RRR and QZ59-SSS, as the guide or residues protected from
methanethiosulfate (MTS) labeling by verapamil (suggesting verapamil
binding site).
RNA Interference Experiments
Synthetic siRNA oligonucleotides targeting ABCB1, CDK7, or
CDK9 (ON-TARGETplus SMARTpool siRNAs) were purchased from
Dharmacon (Lafayette, CO). The nontargeting siRNA (ON-TARGET-
plus SMARTpool; Dharmacon) was used as a negative control. Transfec-
tions were performed using the Neon Transfection System (Invitrogen,
Darmstadt, Germany) according to the manufacturer’s protocol. UKF-
NB-3 cells were grown to about 60% to 80% confluence and trypsinized,
and 2 × 106 cells were resuspended in 200 μl of resuspension buffer
containing 2.5 μM siRNA. Electroporation was performed in a pipette
tip chamber with previously optimized adjustments (voltage of 1400;
width of 20; two pulses). After electroporation, the cells were trans-
ferred into fibronectin (100 μg/ml)–coated six-well plates containing
prewarmed IMDM plus 10% FCS.
Western Blot
Cells were lysed in Triton X-100 sample buffer and separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Pro-
teins were detected using specific antibodies directed against β-actin
(BioVision through BioCat GmbH, Heidelberg, Germany), CDK7,
CDK9, X-linked inhibitor of apoptosis (XIAP), myeloid cell leukemia
sequence 1 (Mcl-1), caspase 3, cleaved poly (ADP-ribose) polymerase
(PARP; all from Cell Signaling Technology through New England
Biolabs, Frankfurt am Main, Germany), RNA polymerase II, Ser-2–
phosphorylated RNA polymerase II, Ser-5–phosphorylated RNA poly-
merase II (all from Abcam, Cambridge, United Kingdom), baculoviral
IAP repeat containing 2 (cIAP-1), survivin (all from R&D Systems),
and cIAP-2 (Epitomics through Abcam). Protein bands were visualized
by enhanced chemiluminescence using a commercially available kit
(Amersham, Freiburg, Germany).
RNA Synthesis Assay
Detection of global RNA synthesis was performed using the Click-iT
RNA HCS Assay (Invitrogen) according to the manufacturer’s pro-
tocol. Cells were seeded in 24-well cell culture plates and allowed to
adhere overnight. Then, the cells were treated with the indicated drug
concentrations for 6 hours. This was followed by 5-ethynyl uridine
(1 mM) labeling for 1 hour at 37°C. The labeled cells were harvested
in flow cytometer tubes, fixed with 4% formaldehyde, and permeabi-
lized (0.1%Triton X-100) before incubation with the Click-iT reaction
buffer (contains Alexa Flour azide) for 30 minutes at room temperature
in the dark. The labeled RNA was quantified using a flow cytometer
(FACSCanto; BD Biosciences, Heidelberg, Germany).
BAX Activity Assay
The cells were fixed and permeabilized using Cytofix/Cytoperm
(BD Biosciences) according to the manufacturer’s protocol. Then,
the cells were incubated with an anti-BAX antibody (clone 6A7;
BD Pharmingen, Heidelberg, Germany) for 30 minutes at 4°C that
specifically recognizes a BAX binding site that is exclusively exposed
on Bax activation in the mitochondrial membrane. After incubation
with a secondary PE-labeled anti-mouse antibody for 30 minutes at
4°C, the percentage of cells displaying activated BAX was quantified
by flow cytometry.
Mitochondrial Membrane Potential (Δψ) Analysis
The mitochondrial membrane potential (Δψ) was examined using
the BD MitoScreen/Flow Cytometry Mitochondrial Membrane
Potential Detection Kit (BD Biosciences) according to the manufac-
turer’s protocol. The cells were harvested and incubated with 5,5′,6,6′-
tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine I-/CI-salt
(JC-1) for 15 minutes at 37°C. After washing twice with assay buffer,
the Δψ was analyzed by flow cytometry.
Cytochrome c Release
The cytochrome c release in apoptotic cells was detected as described
by Waterhouse and Trapani [30]. Cells were harvested, washed with
cold PBS, pelleted, and permeabilized (10 ng/ml digitonin in PBS),
so that cytochrome c released from the mitochondria in apoptotic
cells could be washed away. On fixation with 4% formaldehyde,
cells were incubated for 1 hour at room temperature with blocking
buffer (0.05% saponin and 3% BSA in PBS), followed by incubation
overnight at 4°C with primary anti–cytochrome c antibody (6H2.B4;
BD Pharmingen). After incubation with secondary PE-labeled anti-
mouse antibody for 40 minutes on ice, the cells were analyzed for
their mitochondrial cytochrome c content by flow cytometry.
Caspase 3/7 Activity Assay
The activity of caspases 3 and 7 was examined using the Caspase-Glo
3/7 Assay (Promega GmbH, Mannheim, Germany) following the
manufacturer’s instructions. Cells were seeded in 96-well cell culture
plates and allowed to adhere overnight. After drug treatment, the
culture plates were adjusted to room temperature. Then, the cells
were incubated for 5 minutes with the premixed substrate, and
the luminescent signal was measured with a plate reader (Tecan,
Crailsheim, Germany) for 30 cycles.
Detection of Sub-G1 Cells
For the detection of sub-G1 cells, the intracellular DNA was
stained using propidium iodide (PI). Cells were harvested, washed
with PBS, and fixed with 70% ethanol at −20°C overnight. After
washing the cells with PBS twice, cells were stained for 30 minutes
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with 500 μl of PI solution (20 μg/ml PI and 0.001% Triton X-100
in PBS) at room temperature in the dark. The DNA content of the
cells was quantified by flow cytometry.
Xenograft Experiments
Mouse experiments were performed using male NMRI:nu/nu mice.
UKF-NB-3rCDDP1000 (1 × 107) cells were injected subcutaneously
together with 50% Matrigel (BD Biosciences) into the right flank.
When the tumors reached a palpable size, at day 21, mice were divided
into two groups, each consisting of six animals. SNS-032 treatment
was performed using 30 mg/kg SNS-032 dissolved in aqueous 2.1 mmol
of tartaric acid solution intraperitoneally at days 21, 24, and 27. Con-
trol animals received aqueous 2.1 mmol of tartaric acid solution intra-
peritoneally at the same days. Tumor volumes were measured two
times per week using a caliper. The tumor volumes were calculated
Figure 1. Antineuroblastoma effects of SNS-032 in vitro and in vivo. (A) Concentrations that reduce the viability of parental, chemosensitive
neuroblastoma cell lines and their sublines with acquired resistance to a broad range of different anticancer drug classes by 50% (IC50) or
90% (IC90) as determined by MTT assay after a 5-day treatment period. (B) Effects of SNS-032 (30 mg/kg administered on days 21, 24, and
27) on the growth of subcutaneous UKF-NB-3rCDDP1000 (UKF-NB-3 cells with acquired resistance to cisplatin) xenografts in comparison to
vehicle controls. No tumors were palpable before day 21. *P < .5 compared to vehicle.
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by the formula volume = length × width2/2. The experiments were
terminated when the control tumors reached a size > 1 cm2.
The animal experiments were performed according to the German
Animal Protection Law and with approval from the responsible
authorities (LaGeSo, Berlin, Germany). The procedures were con-
sistent and in compliance with the United Kingdom Coordinating
Committee on Cancer Research (UKCCCR) guidelines.
Results
Anticancer Effects of SNS-032 on Neuroblastoma Cells
In Vitro and In Vivo
SNS-032 was tested in a panel of 109 neuroblastoma cell lines con-
sisting of 19 parental neuroblastoma cell lines and 90 drug-adapted
sublines (Figure 1A and Table W1B). The IC50 values ranged from
Figure 2. Effects of ABCB1 expression on neuroblastoma cell sensitivity to SNS-032. (A) Box plots indicating the SNS-032 concentrations
that reduce the viability of low and high ABCB1-expressing cells in the absence or presence of the ABCB1 inhibitor verapamil (10 μM)
by 50% (IC50) or 90% (IC90) as indicated by MTT assay after 5 days of incubation. (B) Effects of siRNA-mediated depletion of ABCB1 on
the SNS-032 concentrations that reduce UKF-NB-3ABCB1 cell viability by 50% (IC50) or 90% (IC90) as indicated by MTT assay 48 hours after
transfection. *P < .05 relative to siRNA buffer and nontargeting siRNA. (C) Effects of verapamil or SNS-032 on the accumulation of the
fluorescent ABCB1 substrate rhodamine 123 in ABCB1-expressing UKF-NB-3rVCR10 cells; *P < .05 relative to rhodamine 123 alone.
(D) Effects of SNS-032 on the viability of primary neuroblastoma cells in the absence or presence of verapamil (10 μM), *P < .05 rela-
tive to SNS-032 alone. (E) Effect of SNS-032 on the expression of UKF-NB-3 cells transduced with a lentiviral vector encoding for ABCG2
(UKF-NB-3ABCG2) or a control vector (UKF-NB-3piG2) in the absence or presence of the ABCG2 inhibitor Fumitremorgin C (10 μM). *P < .05
relative to non–Fumitremorgin C–treated cells; #P < .05 relative to UKF-NB-3piG2 cells.
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58.3 (NLFrPCL20) to 14,615 nM (IMR-5rDOCE20), and the con-
centrations that reduce cell viability by 90% (IC90) ranged from
106.4 (NLFrPCL20) to >20,000 nM (IMR-5rDOCE20, SHEPrVCR1).
In the parental cells, the IC50 values ranged from 95.7 (NGP) to
1671 nM (UKF-NB-4), and the IC90 values ranged from 152.4 nM
(NLF) to 2611 nM (UKF-NB-4).
In the drug-adapted cell lines, there was, in general, a good cor-
relation between the relative fold changes in the SNS-032 IC50 (IC50
drug-adapted cell/IC50 parental cell) and IC90 values (IC90 drug-
adapted cell/IC90 parental cell) between parental and corresponding
drug-adapted cell lines. A substantial difference was detected only
in NLFrDOCE20 (IC50 NLF
rDOCE20/IC50 NLF = 1.37; IC90
NLFrDOCE20/IC90 NLF = 4.66), UKF-NB-2
rCARBO2000 (IC50
UKF-NB-2rCARBO2000/IC50 UKF-NB-2 = 0.68; IC90 UKF-NB-
2rCARBO2000/IC90 UKF-NB-2 = 3.99), and UKF-NB-2
rOXALI600
(IC50 UKF-NB-2
rOXALI600/IC50 UKF-NB-2 = 0.78; IC90 UKF-
NB-2rOXALI600/IC90 UKF-NB-2 = 4.77) cells compared to the
parental cells.
A significant fraction of the drug-adapted neuroblastoma cell
lines showed a similar SNS-032 sensitivity like the corresponding
parental cells. Fifty-five of the 90 drug-adapted cell lines (61%)
displayed IC50 drug-adapted cell line/IC50 parental cell line and
IC90 drug-adapted cell line/IC90 parental cell line ratios between
0.5 and 2.0. Acquired resistance to tubulin-binding agents and doxo-
rubicin appeared to result generally in cross-resistance to SNS-032.
Seven of 8 taxane (docetaxel, paclitaxel)–adapted cell lines, 12 of
14 vinca alkaloid (vincristine, vinblastine, vinorelbine)–adapted cell
lines, and 4 of 5 doxorubicin-resistant cell lines displayed ratios
of the IC90 resistant cell/IC90 parental cell > 2 (Figure 1A and
Table W1B). All five gemcitabine-resistant sublines remained SNS-
032 sensitive (ratios of the IC90 resistant cell/IC90 parental cell ≤
2), whereas a fraction of the cell lines displaying acquired resis-
tance to platinum drugs (9 of 20), etoposide (2 of 6), melphalan
(2 of 6), or topotecan (2 of 5) displayed also decreased sensitivity
to SNS-032.
The anticancer effects of SNS-032 were further investigated in
primary neuroblastoma cells isolated from the bone marrow of four
patients with metastasized INSS stage 4 (Table W1C ). The effec-
tive concentrations were in the range of those detected in the neuro-
blastoma cell lines.
The effect of SNS-032 on tumor growth in the xenograft model was
investigated using the multidrug-resistant cisplatin-adapted UKF-NB-3
subline UKF-NB-3rCDDP1000. UKF-NB-3rCDDP1000 cells showed
a remarkable cross-resistance (IC90 UKF-NB-3
rCDDP1000/IC90 UKF-
NB-3) to doxorubicin (5.2-fold), melphalan (13.9-fold), and topotecan
(2.4-fold), a moderate cross-resistance to vincristine (1.9-fold), but no
cross-resistance to SNS-032 (0.7-fold; Table W1D).
SNS-032 (30 mg/kg administered on days 1, 4, and 7) significantly
inhibited UKF-NB-3rCDDP1000 xenograft growth without substan-
tially influencing mice body weights. Mean relative tumor volumes
are shown in Figure 1B. Individual tumor growth curves and mouse
body weights are presented in Figure W1.
Figure 3. Relevance of functional p53 for the SNS-032–mediated antineuroblastoma effects. (A) SNS-032 (0.3 μM)–induced induction of
p53 and p21 expression in neuroblastoma cells. (B) Concentrations that reduce neuroblastoma cell viability by 50% (IC50) or 90% (IC90) in
neuroblastoma cells in the absence or presence of functional p53; p53 was depleted in UKF-NB-3p53-shRNA and IMR-32p53-shRNA cells
using a lentiviral vector. UKF-NB-3scr-shRNA and IMR-32scr-shRNA were transduced with a control vector encoding for nontargeted scram-
bled shRNA. The p53 activator nutlin-3 that is known to depend on functional p53 in our model system was used as control. *P < .05
relative to the nontargeting shRNA control; #IC90 > 20 μM.
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Influence of ABCB1 and ABCG2 Expression on Cellular
SNS-032 Sensitivity
Many kinase inhibitors were shown to interfere with ABC transporters
including ABCB1 and ABCG2 [31,32]. SNS-032 had previously been
suggested to be a substrate of ABCB1 [33]. In accordance, our dock-
ing studies suggested a strong interaction of SNS-032 with ABCB1.
SNS-032 was docked into the homology model of human ABCB1
and the three X-ray structures of mouse Abcb1a, with the binding sites
defined using the positions of the co-crystallized ligands, QZ59-RRR
and QZ59-SSS (amino acid residues within 4.5-Å distance), and the
verapamil binding site (residues protected from MTS labeling by
verapamil) as described by Aller et al. [28]. The detailed procedures
and results of our docking study are presented in Figure W2.
Indeed, we detected higher SNS-032 IC50 values in neuroblastoma
cells that display high ABCB1 expression than in neuroblastoma cells
characterized by low ABCB1 expression (Figure 2A and Table W1E).
The ABCB1 inhibitor verapamil sensitized cells that express high
ABCB1 levels to SNS-032 but affected SNS-032 sensitivity in cells
that express low ABCB1 levels to a much lower extent (Figure 2A
and Table W1E). Transduction of low ABCB1-expressing UKF-NB-3
cells with a lentiviral vector encoding for ABCB1 (UKF-NB-3ABCB1)
resulted in a 48-fold increase in the SNS-032 IC90 (Table W1F) and
RNAi-mediated depletion of ABCB1 in UKF-NB-3ABCB1 cells or
addition of the ABCB1 inhibitor verapamil resulted in their resensitiza-
tion to SNS-032 (Figures 2B and W3 and Table W1F ). Moreover,
SNS-032 increased the accumulation of the fluorescent ABCB1 substrate
Figure 4. Apoptosis induction by SNS-032 in neuroblastoma cells. (A) BAX activation, mitochondrial membrane potential (Δψ), fraction
of cytochrome-negative cells, enzymatic caspase 3/7 activity, and fraction of sub-G1 cells in SNS-032–treated UKF-NB-3 and IMR-32
cells. *P < .05 relative to nontreated control. (B) Western blots indicating SNS-032 (300 nM)–induced PARP and caspase-3 cleavage
in UKF-NB-3 and IMR-32 cells.
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rhodamine 123 in highly ABCB1-expressing UKF-NB-3rVCR10 cells
in a concentration-dependent manner (Figure 2C ). Notably, two
of the four primary samples (samples 1 and 2) expressed ABCB1
(Figure W4) and were sensitized by the ABCB1 inhibitor verapamil
(10 μM) to SNS-032 (Figure 2D and Table W1C).
Taken together, these data confirm that the activity of SNS-032 is af-
fected by ABCB1 expression and that SNS-032 affects ABCB1 function.
ABCG2 also interfered with the SNS-032 efficacy, and the ABCG2
inhibitor Fumitremorgin C sensitized ABCG2-expressing cells to SNS-
032, however, to a much lesser extent (Figure 2E and Table W1G ).
Influence of p53 on the Neuroblastoma Cell Response
to SNS-032
SNS-032 treatment induced p53 accumulation and accumulation of
the p53 target gene p21 in UKF-NB-3 and IMR-32 cells (Figure 3A).
To investigate the role of p53 within the cellular response to SNS-
032, we depleted p53 in the p53 wild-type neuroblastoma cell lines
UKF-NB-3 and IMR-32 using a lentiviral vector encoding for p53
shRNA as described before [25]. The p53-depleted cells displayed
decreased sensitivity to the murine double minute 2 (MDM2) inhibitor
nutlin-3 that exerts its antineuroblastoma effects through induction of
p53-mediated apoptosis [24,27,34] but not to SNS-032 (Figure 3B).
Moreover, p53 depletion reduced the UKF-NB-3 cell sensitivity to
the cytotoxic anticancer drugs actinomycin D, cisplatin, melphalan,
and vincristine (Table W1H). Notably, SNS-032 exerted also similar
effects in parental UKF-NB-3 and UKF-NB-6 cells and its sublines
adapted to nutlin-3 harboring different p53 mutations (Figure 1A and
Table W1, B and J). Therefore, p53 does not appear to be critical for
the antineuroblastoma effects exerted by SNS-032.
Influence of SNS-032 on Neuroblastoma Cell Proliferation
and Death
SNS-032 treatment caused clear features of apoptotic cell death in
neuroblastoma cells. SNS-032 induced BAX activation, reduced the
mitochondrial membrane potential, provoked mitochondrial cyto-
chrome c release, enhanced the enzymatic caspase 3/7 activity, and
increased the number of sub-G1 cells in a concentration-dependent
manner in UKF-NB-3 and IMR-32 cells (Figure 4A). Western blots
Figure 5. Effects of SNS-032 on CDK7 and CDK9 signaling, RNA synthesis, and expression of antiapoptotic proteins in neuroblastoma
cells. (A) Effects of SNS-032 (300 nM) on CDK7 expression and the expression and phosphorylation [p-RNA pol II (Ser-5)] of its down-
stream RNA polymerase II (RNA pol II) and on CDK9 expression and the expression and phosphorylation [p-RNA pol II (Ser-2)] of its
downstream RNA pol II. (B) UKF-NB-3 or IMR-32 cells were treated for 6 hours with SNS-032 or actinomycin D (ActD, positive control
for RNA synthesis inhibition) before the determination of RNA synthesis activity. *P < .05 relative to nontreated control. (C) Western
blots indicating cellular levels of antiapoptotic proteins with high turnover rates in SNS-032 (300 nM)–treated neuroblastoma cells.
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detected caspase 3 cleavage indicating caspase 3 activation and PARP
cleavage, an additional characteristic of apoptosis (Figure 4B).
Effects of SNS-032 on CDK7 and CDK9
SNS-032 reduced CDK7 and CDK9 expression in the neuro-
blastoma cell lines UKF-NB-3 and IMR-32 and interfered with
the downstream signaling of these CDKs (Figure 5). CDK7 and
CDK9 are involved in transcription. CDK7 phosphorylates RNA
polymerase II at Ser-5 as a member of the transcription factor com-
plex TFIIH and promotes transcription initiation [35]. CDK9 phos-
phorylates RNA polymerase II at Ser-2 as a member of the elongation
factor complex P-TEFb and promotes elongation [36]. SNS-032
interfered with RNA polymerase II phosphorylation at both phos-
phorylation sides (Figure 5A). In accordance with its effects on
RNA polymerase II, SNS-032 also inhibited RNA synthesis in a
concentration-dependent manner in UKF-NB-3 and IMR-32 cells
(Figure 5B).
In chronic myeloid leukemia cells, RNA synthesis inhibition by
SNS-032 resulted in decreased cellular levels of the antiapoptotic
proteins Mcl-1 and XIAP that have a high turnover rate [5]. Simi-
larly, SNS-032 reduced the levels of Mcl-1, XIAP, cIAP, and survivin
in neuroblastoma cells (Figure 5C ).
Next, we investigated the effects of siRNA-mediated depletion of
CDK7 and CDK9 on RNA synthesis and viability in UKF-NB-3 cells.
Results revealed that inhibition of CDK9 resulted in the strongest effects,
which were further enhanced in combination with CDK7 (Figure 6).
Discussion
Acquired drug resistance represents a major problem in the successful
treatment of neuroblastoma [18,19]. Therefore, additional treatment
Figure 6. Effects of RNAi-mediated depletion of CDK7 and/or CDK9 on UKF-NB-3 neuroblastoma cell viability. (A) Western blot showing
siRNA-mediated depletion of CDK7 and/or CDK9 in UKF-NB-3 cells as determined 48 hours after. (B) Effects of CDK7 and/or CDK9
depletion on RNA synthesis 48 hours after transfection; *P < .05 relative to nontargeting siRNA, #P < .05 relative to CDK9 siRNA.
(C) Effects of CDK7 and/or CDK9 depletion on the number of sub-G1 cells 48 hours after transfection; *P < .05 relative to nontargeting
siRNA, #P < .05 relative to CDK9 siRNA. (D) Representative photographs showing cancer cell cultures 48 hours after transfection.
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options are needed to improve the therapy outcome for patients that
cannot be treated satisfactorily by the current therapy regimens. Here,
we investigated the effects of SNS-032 in a panel of 109 neuroblastoma
cell lines consisting of 19 parental neuroblastoma cell lines and 90 sub-
lines with acquired resistance to 14 different anticancer drugs. The
results indicated that neuroblastoma cell resistance acquisition to
certain drugs is more likely to result in cross-resistance to SNS-032
than resistance acquisition to other drugs. The resistance acquisition
to taxanes, vinca alkaloids, and doxorubicin appeared to be in general
(but not always) associated with a reduced sensitivity to SNS-032. All
five gemcitabine-resistant cell lines retained sensitivity to SNS-032,
whereas half or less of the platinum drug-, melphalan-, etoposide-, or
topotecan-resistant cell lines displayed cross-resistance to SNS-032.
These findings confirm previous assumptions that a drug needs to be
investigated in many cancer cell lines to receive a reasonable idea of its
possible therapeutic potential in a certain cancer entity [37]. Moreover,
our results are in accordance with previous studies performed in
mantle cell lymphoma cells that had indicated the SNS-032 response
to depend on the biologic context of each individual cell line [7].
Therapeutic SNS-032 plasma concentrations were reported to range
from 176 to 754 nM in clinical trials in adults [12]. Because data on
the SNS-032 pharmacokinetics in children are missing, we used the
data derived from adults to analyze our findings. The viability of a sig-
nificant fraction of the investigated cell lines was affected in this concen-
tration range. Fifty-two of the investigated 109 cell lines (48%) displayed
an SNS-032 IC50 value lower than 176 nM, and 14 cell lines (13%) dis-
played an SNS-032 IC90 value lower than 176 nM. Eighty of the 109
cell lines (73%) displayed an IC50 smaller than 754 nM, and 68 (62%)
displayed an IC90 below 754 nM. Among the parental cell lines, 9 of
19 cell lines (47%) displayed an IC50 below 176 nM and 3 (16%) dis-
played an IC90 below 176 nM. Seventeen parental cell lines (89%) dis-
played an IC50 below 754 nM, and 13 (68%) displayed an IC90 below
754 nM. Moreover, all four primary neuroblastoma samples had IC50
values below 754 nM, and the IC90 values of two of the samples were
also below 754 nM. On the basis of these findings, SNS-032 may rep-
resent a treatment option for a fraction of patients with neuroblastoma.
In animal experiments, SNS-032 inhibited the growth of cisplatin-
resistant UKF-NB-3rCDDP1000 cells that display cross-resistance to a
range of anticancer drugs. This confirms that SNS-032 is also active
against neuroblastoma under in vivo conditions. Possibly, the in vivo
efficacy of SNS-032 could be further enhanced by optimized applica-
tion schemes in our model. However, it is unlikely that a compound
would be introduced clinically as a monotherapy for recurrent neuro-
blastoma. Our preliminary results suggest that SNS-032 may exert
enhanced antineuroblastoma effects in combination with cytotoxic
anticancer drugs including cisplatin, melphalan, and topotecan (Fig-
ure W5). Therefore, the focus of follow-up studies should probably
be on effective combination therapies.
Pharmacokinetic studies in rats had indicated that SNS-032 was
an ABCB1 substrate [33]. We performed in silico docking studies
that confirmed SNS-032 to be a potential ABCB1 substrate. Indeed,
ABCB1 expression was correlated with decreased neuroblastoma
cell sensitivity to SNS-032. Pharmacological inhibition or RNAi-
mediated depletion of ABCB1 strongly sensitized ABCB1-expressing
cells to SNS-032. ABCB1 may be a dominant SNS-032 resistance
mechanism in neuroblastoma. In the presence of the ABCB1 inhib-
itor verapamil, the IC50 values of all 30 neuroblastoma cell lines
that had displayed IC50 values > 754 nM were reduced to values <
754 nM. Moreover, the IC90 values of 39 of the 41 cell lines (95%)
that had IC90 values > 754 nM were reduced to therapeutic con-
centrations < 754 nM in the presence of verapamil (Table W1K ). In
contrast, ABCG2 expression only modestly affected neuroblastoma cell
sensitivity to SNS-032. This demonstrates that ABCB1 expression is a
major SNS-032 resistance mechanism in neuroblastoma. The clinical
role of ABCB1 expression in neuroblastoma remains unclear [18,38].
At diagnosis, few neuroblastoma cells appear to express ABCB1 and
the prognostic relevance of ABCB1 expression appears to be limited
[39,40]. However, ABCB1 expression might represent an acquired
resistance mechanism in neuroblastoma [41].
The formation of p53 mutations was suggested to be an acquired
resistance mechanism in neuroblastoma [19]. In general, p53 muta-
tions were described to be rare in neuroblastoma. However, while
p53 was found mutated in only 2% of neuroblastomas at diagnosis,
p53 mutations were detected in about 15% of neuroblastomas at
relapse [19,42,43]. Moreover, p53 mutations represented an inde-
pendent prognostic factor for overall survival in neuroblastoma
[19,42]. In accordance, the analysis of two cell lines derived from the
same patient revealed that the cell line established from the primary
tumor before cytotoxic therapy harbored wild-type p53, whereas the
cell line derived after cytotoxic therapy harbored a p53 mutation
[44]. These findings are also consistent with studies in preclinical
neuroblastoma models demonstrating that the loss of p53 function is
associated with resistance to multiple anticancer drugs and radiotherapy
and that resistance acquisition to anticancer drugs may be associated
with p53 mutations [19,22,24,45–48]. In addition, abnormalities in
the p53/MDM2/p14ARF pathway different from p53 mutations were
detected in 35% of the neuroblastoma samples indicating that p53
signaling is substantially impaired by varying mechanisms in 50% of
neuroblastomas [19,42]. Consequently, drugs that exert their anti-
neuroblastoma effects independently of the presence of functional
p53 are highly desirable. Notably, SNS-032 (but not the cytotoxic
drugs actinomycin D, cisplatin, melphalan, or vincristine) displayed
the same efficacy in neuroblastoma cells in the absence or presence of
functional p53.
The anticancer mechanism of SNS-032 in neuroblastoma cells
apparently resembles the anticancer mechanism that was described
for SNS-032 in chronic myeloid leukemia cells [5]. SNS-032 inhib-
ited CDK7 and CDK9 expression and reduced the phosphorylation
of the CDK7 and CDK9 downstream RNA polymerase II. This
resulted in the suppression of RNA synthesis and decreased cellular
levels of antiapoptotic proteins with a high turnover rate including
Mcl-1, XIAP, cIAP-1, and survivin. RNAi-mediated depletion of
CDK9 (but not of CDK7) resulted in substantial antineuroblastoma
effects. Therefore, our findings appear to be in line with recent studies
suggesting CDK9 to be a critical anticancer drug target among the
CDKs [49]. Notably, the effects of CDK9 depletion were significantly
further enhanced by simultaneous CDK7 depletion.
Taken together, SNS-032 and other therapy strategies that target
CDK7 and CDK9 represent potential treatment options for neuro-
blastoma including therapy-refractory cases.
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Figure W1. Antineuroblastoma effects of SNS-032 in vivo. Effects of SNS-032 (30 mg/kg administered on days 21, 24, and 27) on the
growth of subcutaneous UKF-NB-3rCDDP1000 (UKF-NB-3 cells with acquired resistance to cisplatin) xenografts (A) and on mice body
weights (B) in comparison to vehicle controls.
Figure W2A. Docking studies on the interaction of SNS-032 with ABCB1. SNS-032 was docked into the homology model of human
ABCB1 and the three X-ray structures of mouse Abcb1a, with the binding sites defined using the positions of the co-crystallized ligands,
QZ59-RRR and QZ59-SSS (amino acid residues within 4.5-Å distance), and the verapamil binding site (residues protected from MTS
labeling by verapamil) as described by Aller et al. [28]. (A) A summary of the top-scoring poses. Using all binding site definitions, docking
into 3G60 and 3G61, which are the structures of ABCB1 with co-crystallized ligands, generated consistently better binding scores than
docking 3G5U, the structure crystallized in the absence of a ligand. The best binding scores in all cases were achieved when the biding
site was defined using the co-crystallized QZ59-SSS. Results indicated that the basic scaffold of SNS-032 makes several strong bonds at
the binding pocket of QZ59-SSS. The top 30 retained poses for each binding pocket showed consistency in terms of the amino acids
involved in the interaction (B). (C) A list of the interactions for the top poses. These interacting residues sit in transmembrane helices 7,
10, 11, and 12. They are all within the list of residues facing the internal cavity of ABCB1 within the lipid bilayer as described by Aller et al.
[28]. The only exception from this is Ser-725, which, in 3 of 30 poses, is involved in hydrogen bonding with the nitrogen atom of the
thiazole ring in 3G60 structure (B and D). SNS-032 was docked into different binding sites of ABCB1 structures (mouse and human). The
flexibility and polyspecificity of ABCB1 can lead to the uncertainty of scoring functions. Therefore, docking studies in this work consid-
ered sampling a large number of docking poses incorporating four different protein structures with four different binding site definitions
in each structure. The results identified residues in the binding sites that were involved in a high number of docking poses (>10%).
These amino acids are all part of the internal cavity of ABCB1 within the lipid bilayer with only one exception and sit within transmembrane
helices 1, 3, 5, 6, 7, 11, and 12 (E). The preferential binding site for SNS-032 was suggested to be close to the binding site of cyclic-tris-(S )-
valineselenazole (QZ59-SSS) in the mouse Abcb1a X-ray structures and the human homology model of this protein. Our results indicate
several strong hydrogen bonding interactions in mouse and human ABCB1 (D and F), which is a characteristic of the more hydrophilic
lower QZ59-SSS binding site. These are accompanied by several H-Pi and Pi-Pi interactions including interactions between Val-982 of human
ABCB1 (also protected from MTS labeling by verapamil) and oxazole ring and Phe-978 and dimethylpropane group (D). Protein interaction
energies (kcal/mol) of the four top-scoring poses; binding site is that of verapamil, the cyclic hexapeptide inhibitors (QZ59-RRR and QZ59-
SSS) separately, or the residues involved in both QZ59-RRR and QZ59-SSS binding sites. Number of poses retained was 30 or higher. The
highest interaction energies are highlighted in bold.
Figure W2B. The population histogram for the 30 SNS-032/ABCB1 docking poses at the QZ59-SSS binding site. Complexes are shown
along the Y-axis, and the residues corresponding to each group of fingerprint bits on the X-axis are coded with an arbitrary sequence of
colors. (A) Human model of ABCB1. (B) 3G60. (C) 3G61. (D) 3G5U.
Figure W2C. Ligand interactions report for SNS-032 at the first pose using QZ59-SSS lower binding site.
Figure W2D. Interaction of SNS-032 with QZ59-SSS binding site of 3G60 using MOE software. Ligand interaction 2D diagrams indicate
the polar and nonpolar interactions by pink or green amino acids, hydrogen bonding by green dotted arrows, and Pi-H interactions
with green dotted line. In this diagram, the energy cutoff for H-bond and ionic interactions was−0.5 kcal/mol and the maximum distance
for nonbonded groups was 4.5 Å. Proximity contours are dotted lines surrounding the ligand and indicate the shape of the binding site and
available space to the more outward-facing parts of the ligand. Blue shadows in some amino acids indicate the receptor exposure differences
by the size and intensity of the quoits disks. The directions of the shadow indicate the directions of the amino acids toward the ligands. The
blue clouds around the ligand atoms indicate the solvent exposure.
Figure W2E. The most common interacting residues with SNS-032 in docking poses and their location in the transmembrane helices of
ABCB1; residues in brackets are residue numbers in mouse.
Figure W2F. Interaction of SNS-032 with verapamil binding site of human ABCB1 using MOE software. Ligand interaction 2D diagrams
indicate the polar and nonpolar interactions by pink or green amino acids, hydrogen bonding by green dotted arrows, and Pi-H interactions
with green dotted line. In this diagram, the energy cutoff for H-bond and ionic interactions was −0.5 kcal/mol and the maximum distance for
nonbonded groups was 4.5 Å. Proximity contours are dotted lines surrounding the ligand and indicate the shape of the binding site and available
space to the more outward-facing parts of the ligand. Blue shadows in some amino acids indicate the receptor exposure differences by the size
and intensity of the quoits disks. The directions of the shadow indicate the directions of the amino acids toward the ligands. The blue clouds
around the ligand atoms indicate the solvent exposure [28].
Figure W4. ABCB1 expression in primary neuroblastoma samples.Figure W3. siRNA-mediated depletion of ABCB1 in UKF-NB-3ABCB1
cells. ABCB1expression and accumulation of the fluorescent ABCB1
substrate rhodamine 123 in UKF-NB-3ABCB1 cells 48 hours after
transfection with siRNA directed against ABCB1. *P < .05 relative
to control.
Figure W5. (A) Antineuroblastoma activity of SNS-032 in combination with cytotoxic anticancer drugs in UKF-NB-3 cells. Cell viability was
determined relative to nontreated control cells by MTT after 5 days of incubation. *P< .05 relative to SNS-032 and cytotoxic drug; n.d., not
detectable cell viability. (B) Antineuroblastoma activity of SNS-032 in combinationwith cytotoxic anticancer drugs in UKF-NB-3 cells resistant
to cisplatin (UKF-NB-3rCDDP1000), melphalan (UKF-NB-3rMEL400), or topotecan (UKF-NB-3rTOPO15). Cell viability was determined relative to
nontreated control cells byMTT after 5 days of incubation. *P< .05 relative to SNS-032 and cytotoxic drug; n.d., not detectable cell viability.
Figure W5. (continued).
